☰

Koen Van Herck, Ph.D. - Publications

Affiliations: 
2006 Universiteit Antwerpen (Belgium) 
Area:
Public Health
Tree Info Similar researchers PubMed Report error

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence. Human Vaccines & Immunotherapeutics. 1-24. PMID 33325760 DOI: 10.1080/21645515.2020.1819742  0.734
2016 Sabbe M, Berger N, Blommaert A, Ogunjimi B, Grammens T, Callens M, Van Herck K, Beutels P, Van Damme P, Bilcke J. Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveillance : Bulletin EuropéEn Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 21. PMID 27418466 DOI: 10.2807/1560-7917.Es.2016.21.27.30273  0.711
2015 Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 33: 5723-7. PMID 26190091 DOI: 10.1016/J.Vaccine.2015.07.008  0.703
2015 Van Herck K, Hens A, De Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine. The Pediatric Infectious Disease Journal. 34: e85-91. PMID 25389920 DOI: 10.1097/INF.0000000000000616  0.726
2014 Verhaegen J, Flamaing J, De Backer W, Delaere B, Van Herck K, Surmont F, Van Laethem Y, Van Damme P, Peetermans W. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011. Euro Surveillance : Bulletin EuropéEn Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 19: 14-22. PMID 25138972 DOI: 10.2807/1560-7917.ES2014.19.31.20869  0.453
2014 Matthijnssens J, Zeller M, Heylen E, De Coster S, Vercauteren J, Braeckman T, Van Herck K, Meyer N, Pirçon JY, Soriano-Gabarro M, Azou M, Capiau H, De Koster J, Maernoudt AS, Raes M, et al. Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 20: O702-10. PMID 24580887 DOI: 10.1111/1469-0691.12612  0.575
2014 Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine. 32: 1507-13. PMID 24508042 DOI: 10.1016/J.Vaccine.2013.10.088  0.667
2012 Braeckman T, Van Herck K, Meyer N, Pirçon JY, Soriano-Gabarró M, Heylen E, Zeller M, Azou M, Capiau H, De Koster J, Maernoudt AS, Raes M, Verdonck L, Verghote M, Vergison A, et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. Bmj (Clinical Research Ed.). 345: e4752. PMID 22875947 DOI: 10.1136/bmj.e4752  0.625
2012 Braeckman T, Van Herck K, Jilg W, Bauer T, Van Damme P. Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory. Vaccine. 30: 4757-61. PMID 22652400 DOI: 10.1016/j.vaccine.2012.05.044  0.687
2012 Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Human Vaccines & Immunotherapeutics. 8: 323-7. PMID 22327499 DOI: 10.4161/hv.18617  0.666
2012 Van Damme P, Leroux-Roels G, Crasta P, Messier M, Jacquet JM, Van Herck K. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. Journal of Medical Virology. 84: 11-7. PMID 22052690 DOI: 10.1002/jmv.22264  0.736
2011 Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. Journal of Medical Virology. 83: 1885-91. PMID 21915861 DOI: 10.1002/jmv.22200  0.735
2011 Hanquet G, Ducoffre G, Vergison A, Neels P, Sabbe M, Van Damme P, Van Herck K. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine. 29: 4698-703. PMID 21571023 DOI: 10.1016/j.vaccine.2011.04.098  0.702
2011 Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. The Pediatric Infectious Disease Journal. 30: S21-4. PMID 21183836 DOI: 10.1097/INF.0b013e3181fefc51  0.712
2011 Asnong C, Van Herck K, Lernout T, Theeten H, Van Damme P. Lessons learned from a measles outbreak in Antwerp, Belgium 2007-2008. The Pediatric Infectious Disease Journal. 30: 343-5. PMID 20924311 DOI: 10.1097/INF.0b013e3181fbf5b7  0.69
2010 Van Damme P, Zanetti AR, Shouval D, Van Herck K. Strategies for global prevention of hepatitis B virus infection. Advances in Experimental Medicine and Biology. 659: 175-88. PMID 20204764 DOI: 10.1007/978-1-4419-0981-7_14  0.458
2009 Vorsters A, Van Herck K, Van Damme P. The clock is running, ... Vaccine. 27: 2905-6. PMID 19428900 DOI: 10.1016/j.vaccine.2009.01.124  0.324
2009 David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecologic Oncology. 115: S1-6. PMID 19217149 DOI: 10.1016/j.ygyno.2009.01.011  0.645
2009 De Hert M, Wampers M, Van Eyck D, Peuskens J, Franic T, Vidovic D, Van Herck K, Van Damme P. Prevalence of HIV and hepatitis C infection among patients with schizophrenia. Schizophrenia Research. 108: 307-8. PMID 19091513 DOI: 10.1016/j.schres.2008.11.008  0.383
2008 Van Herck K, Vorsters A, Van Damme P. Prevention of viral hepatitis (B and C) reassessed. Best Practice & Research. Clinical Gastroenterology. 22: 1009-29. PMID 19187864 DOI: 10.1016/j.bpg.2008.11.008  0.655
2008 Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, Ropero AM, Shouval D, Ward W, Van Damme P. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Journal of Viral Hepatitis. 15: 1-15. PMID 18837827 DOI: 10.1111/j.1365-2893.2008.01022.x  0.665
2008 Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. The Pediatric Infectious Disease Journal. 27: 861-9. PMID 18776823 DOI: 10.1097/INF.0b013e318173966f  0.689
2007 Van Herck K, Leuridan E, Van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sexually Transmitted Infections. 83: 426-32. PMID 17911142 DOI: 10.1136/sti.2006.022111  0.73
2007 Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Medicine and Infectious Disease. 5: 171-5. PMID 17448944 DOI: 10.1016/j.tmaid.2006.07.003  0.695
2007 Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Medicine and Infectious Disease. 5: 79-84. PMID 17298912 DOI: 10.1016/j.tmaid.2006.04.004  0.755
2007 Wouters K, Leuridan E, Van Herck K, Van Ardenne N, Roelofs I, Mak R, Prévost C, Guérin P, Denis B, Van Damme P. Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium. Vaccine. 25: 1893-900. PMID 17239492 DOI: 10.1016/j.vaccine.2006.09.073  0.699
2005 Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Review of Vaccines. 4: 459-71. PMID 16117704 DOI: 10.1586/14760584.4.4.459  0.736
2005 Van Damme P, Van Herck K. Effect of hepatitis A vaccination programs. Jama. 294: 246-8. PMID 16014600 DOI: 10.1001/jama.294.2.246  0.686
2005 Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, Leroux-Roels G, Van Herck K, Bollaerts A, Dubin G. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 40: 1271-81. PMID 15825029 DOI: 10.1086/429240  0.473
2004 Van Damme PA, Van Herck K, Banatvala JE. Do we need hepatitis A booster vaccinations? Journal of Travel Medicine. 11: 179-80. PMID 15710060 DOI: 10.2310/7060.2004.18479  0.744
2004 Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Review of Vaccines. 3: 249-67. PMID 15176942 DOI: 10.1586/14760584.3.3.249  0.734
2004 Van Herck K, Van Damme P. Hepatitis A vaccine. The New England Journal of Medicine. 350: 2211-2; author reply. PMID 15152071 DOI: 10.1056/NEJM200405203502121  0.743
2004 Van Herck K, Castelli F, Zuckerman J, Nothdurft H, Van Damme P, Dahlgren AL, Gargalianos P, Lopéz-Vélez R, Overbosch D, Caumes E, Walker E, Gisler S, Steffen R. Knowledge, Attitudes and Practices in Travel-related Infectious Diseases: The European Airport Survey Journal of Travel Medicine. 11: 3-8. PMID 14769280 DOI: 10.2310/7060.2004.13609  0.361
2004 Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. Journal of Medical Virology. 72: 194-6. PMID 14695659 DOI: 10.1002/jmv.10574  0.641
2004 Van Damme P, Van Herck K, Van der Wielen M. Combined hepatitis A and B vaccine in elderly. Vaccine. 22: 303-4. PMID 14670309  0.721
2003 Zuckerman JN, Van Damme P, Van Herck K, Löscher T. Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. Travel Medicine and Infectious Disease. 1: 219-26. PMID 17291921 DOI: 10.1016/j.tmaid.2003.10.001  0.736
2003 Connor BA, Van Herck K, Van Damme P. Rapid protection and vaccination against hepatitis A for travellers. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 17: 19-21. PMID 12785874  0.74
2003 Van der Wielen M, Van Damme P, Van Herck K, Schlegel-Haueter S, Siegrist CA. Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium). Vaccine. 21: 2412-7. PMID 12744872  0.553
2003 Van Herck K, Zuckerman J, Castelli F, Van Damme P, Walker E, Steffen R. Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. Journal of Travel Medicine. 10: 75-8. PMID 12650648  0.365
2000 Van Herck K, Beutels P, Van Damme P, Beutels M, Van Den Dries J, Briantais P, Vidor E. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines Journal of Medical Virology. 60: 1-7. PMID 10568755 DOI: 10.1002/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H  0.676
1999 Van Herck K, Van Damme P, Collard F, Thoelen S. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years. Scandinavian Journal of Gastroenterology. 34: 1236-40. PMID 10636072 DOI: 10.1080/003655299750024760  0.676
1998 Van Herck K, Van Damme P, Thoelen S, Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results Vaccine. 16: 1933-1935. PMID 9796046 DOI: 10.1016/S0264-410X(98)00126-1  0.717
Show low-probability matches.